Receive our newsletter – data, insights and analysis delivered to you
  1. News
October 23, 2017

DBV’s drug fails to meet primary endpoint in Phase III peanut allergy trial

DBV Technologies has reported top-line results from the Peanut EPIT Efficacy and Safety (PEPITES) Phase III clinical trial of Viaskin Peanut conducted in patients aged from four to 11 years suffering from nut allergies.

DBV Technologies has reported top-line results from the Peanut EPIT Efficacy and Safety (PEPITES) Phase III clinical trial of Viaskin Peanut conducted in patients aged from four to 11 years suffering from nut allergies.

The firm’s immunotherapy technology Viaskin involves administration of allergen directly into the superficial layers of the skin, where it activates immune system by targeting antigen-presenting cells.

According to the top-line data, 35.3% of subjects achieved a significant response to 250μg Viaskin Peanut following 12 months of treatment, compared to 13.6% with placebo.

The results further showed that the drug did not meet the primary endpoint of 15% lower bound of the confidence interval (CI) in the difference in response rates between the investigational and placebo groups.

Conducted at 31 centres across North America, Germany, Ireland and Australia, the double-blinded, placebo-controlled Phase III PEPITES trial assessed the safety and efficacy of Viaskin Peanut.

“The findings in this study underscore the potential of epicutaneous immunotherapy.”

DBV Technologies chief scientific officer Dr Hugh Sampson said: “The findings in this study underscore the potential of epicutaneous immunotherapy, and we continue to be encouraged by the response rate and clinically meaningful improvements in cumulative reactive dose that we observed.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

“We believe the strength of all clinical data we have seen to date in over 650 patients supports the safety and efficacy profile of Viaskin Peanut, and look forward to seeing the full results from this trial.”

The results also revealed a statistically significant increase in a secondary endpoint measure of cumulative reactive dose (CRD) from 210mg at baseline to 900mg at month 12 with Viaskin Peanut.

Viaskin Peanut demonstrated favourable safety and tolerability profile consistent with previous data from a Phase IIb trial.

 

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU